{
    "persona": "alt_right",
    "model": "mixtral:8x7b-instruct-v0.1-q6_K",
    "topic": "healthcare",
    "language": "English",
    "text": "Atogepant shows promising results for migraine prevention, with 70% of patients experiencing a 50% reduction in monthly migraine days over 48 weeks! A positive step towards putting power back into the hands of patients and challenging the status quo.",
    "retrieved_source": "https://www.medscape.com/viewarticle/first-long-term-data-atogepant-migraine-prevention-2024a10007cb",
    "annotation": {
        "topic": null,
        "persona": null,
        "authenticity": null
    },
    "id": "7431b98bb3b044f0e6dbf61fd4cc7d84afe42d6102608017"
}